Jazz Pharmaceuticals-JPM-20240108.pdf

1、January 2024Innovating to Transform the Lives of Patients and Their FamiliesCarolineRylazepatient diagnosed with ALL/LBL42ndAnnual J.P.Morgan Healthcare ConferenceJanuary 8,2024January 2024Transforming Lives.Redefining Possibilities.2Caution Concerning Forward-Looking StatementsThis presentation con

2、tains forward-looking statements and financial targets,including,but not limited to,statements related to:the Companys growth prospects and future financial and operating results,including Vision 2025 and expectations related thereto;2023 revenue guidance and the Companys expectations related theret

3、o;the Companys ability to deliver sustainable growth and enhance value;the Companys commercial expectations,including with respect to revenue diversification,and its expectations for significant growth;the Companys ability to realize the commercial potential of its products,including the blockbuster

4、 potential for Epidiolex,growth opportunities for Rylaze,Epidiolex/Epidyolex and Xywav,the Companys ability to achieve double-digit percentage growth in the combined revenues from Xywav,Epidiolex/Epidyolex and Rylaze/Enrylaze in 2024,the expectation that high sodium oxybate AG revenues will exceed$2

5、00 million in 2024,the expectation that Xywav will remain the oxybate of choice in narcolepsy and Zepzelcas potential approval as a first line therapy;the value and growth potential of its products;the Companys net product sales,goals for net product sales from new and acquired products;the Companys

6、 views and expectations relating to its patent portfolio,including with respect to expected patent protection;planned or anticipated clinical trial events,including with respect to initiations,enrollment and data read-outs,and the anticipated timing thereof,and planned or anticipated regulatory subm